Blood stream infection after hematopoietic stem cell transplantation is associated with increased mortality

Bone Marrow Transplantation

Volumn 40, Issue 1, 2007, Pages 63-70

  Poutsiaka, D D ^a   Price, L L ^a   Ucuzian, A ^b   Chan, G W ^a   Miller, K B ^a   Snydman, D R ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; COTRIMOXAZOLE; CYCLOSPORIN; FLUCONAZOLE; HLA ANTIGEN; IMMUNOGLOBULIN; METHOTREXATE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALPHA HEMOLYTIC STREPTOCOCCUS; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BACTERIUM ISOLATE; CANDIDA; COAGULASE NEGATIVE STAPHYLOCOCCUS; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; ENTEROBACTER; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; FATALITY; FEMALE; FUNGEMIA; FUNGUS; GRAM NEGATIVE BACTERIUM; HLA MATCHING; HUMAN; INFECTIOUS COMPLICATION; KLEBSIELLA; LEUCONOSTOC; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOSIS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; RISK FACTOR; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; VANCOMYCIN RESISTANT ENTEROCOCCUS; VIREMIA; VIRUS INFECTION;

ADULT; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFECTION; MALE; MIDDLE AGED; ODDS RATIO; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 34347388216     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705690     Document Type: Article

References (45)

1. Williamson EC, Millar MR, Steward CG, Cornish JM, Foot AB, Oakhill A et al. Infections in adults undergoing unrelated donor bone marrow transplantation. Br J Haematol 1999; 104: 560-568.
2. Ninin E, Milpied N, Moreau P, Andre-Richet B, Morineau N, Mahe B et al. Longitudinal study of bacterial, viral, and fungal infections in adult recipients of bone marrow transplants. Clin Infect Dis 2001; 33: 41-47.
3. Engels EA, Ellis CA, Supran SE, Schmid CH, Barza M, Schenkein DP et al. Early infection in bone marrow transplantation: Quantitative study of clinical factors that affect risk. Clin Infect Dis 1999; 28: 256-266.
4. Engelhard D, Elishoov H, Strauss N, Naparstek E, Nagler A, Simhon A et al. Nosocomial coagulase-negative staphylococcal infections in bone marrow transplantation recipients with central vein catheter. A 5-year prospective study. Transplantation 1996; 61: 430-434.
5. Lenssen P, Bruemmer BA, Bowden RA, Gooley T, Aker SN, Mattson D. Intravenous lipid dose and incidence of bacteremia and fungemia in patients undergoing bone marrow transplantation. Am J Clin Nutr 1998; 67: 927-933.
6. Sparrelid E, Hagglund H, Remberger M, Ringden O, Lonnqvist B, Ljungman P et al. Bacteraemia during the aplastic phase after allogeneic bone marrow transplantation is associated with early death from invasive fungal infection. Bone Marrow Transplant 1998; 22: 795-800.
7. Busca A, Saroglia EM, Giacchino M, Vai S, Vassallo E, Fagioli F et al. Analysis of early infectious complications in pediatric patients undergoing bone marrow transplantation. Support Care Cancer 1999; 7: 253-259.
8. Barton T, Collis T, Stadtmauer E, Schuster M. Infectious complications the year after autologous bone marrow transplantation or peripheral stem cell transplantation for treatment of breast cancer. Clin Infect Dis 2001; 32: 391-395.
9. Kersun LS, Propert KJ, Lautenbach E, Bunin N, Demichele A. Early bacteremia in pediatric hematopoietic stem cell transplant patients on oral antibiotic prophylaxis. Pediatr Blood Cancer 2005; 45: 162-169.
10. Almyroudis NG, Fuller A, Jakubowski A, Sepkowitz K, Jaffe D, Small TN et al. Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis 2005; 7: 11-17.
11. Winston DJ, Schiffman G, Wang DC, Feig SA, Lin CH, Marso EL et al. Pneumococcal infections after human bonemarrow transplantation. Ann Intern Med 1979; 91: 835-841.
12. Elishoov H, Or R, Strauss N, Engelhard D. Nosocomial colonization, septicemia, and Hickman/Broviac catheter-related infections in bone marrow transplant recipients. A 5-year prospective study. Medicine 1998; 77: 83-101.
13. Romano V, Castagnola E, Dallorso S, Lanino E, Calvi A, Silvestro S et al. Bloodstream infections can develop late (after day 100) and/or in the absence of neutropenia in children receiving allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 23: 271-275.
14. Ortega M, Rovira M, Almela M, Marco F, de la Bellacasa JP, Martinez JA et al. Bacterial and fungal bloodstream isolates from 796 hematopoietic stem cell transplant recipients between 1991 and 2000. Ann Hematol 2005; 84: 40-46.
15. Tsakona CP, Khwaja A, Goldstone AH. Does treatment with haemopoietic growth factors affect the incidence of bacteraemia in adult lymphoma transplant recipients? Bone Marrow Transplant 1993; 11: 433-436.
16. Yuen KY, Woo PC, Hui CH, Luk WK, Chen FE, Lie AK et al. Unique risk factors for bacteraemia in allogeneic bone marrow transplant recipients before and after engraftment. Bone Marrow Transplant 1998; 21: 1137-1143.
17. Ruescher TJ, Sodeifi A, Scrivani SJ, Kaban LB, Sonis ST. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 1998; 82: 2275-2281.
18. Labarca JA, Leber AL, Kern VL, Territo MC, Brankovic LE, Bruckner DA et al. Outbreak of Stenotrophomonas maltophilia bacteremia in allogenic bone marrow transplant patients: Role of severe neutropenia and mucositis. Clin Infect Dis 2000; 30: 195-197.
19. Mitchell AE, Derrington P, Turner P, Hunt LP, Oakhill A, Marks DI. Gram-negative bacteraemia (GNB) after 428 unrelated donor bone marrow transplants (UD-BMT): Risk factors, prophylaxis, therapy and outcome. Bone Marrow Transplant 2004; 33: 303-310.
20. Collin BA, Leather HL, Wingard JR, Ramphal R. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis 2001; 33: 947-953.
21. Koc Y, Snydman DR, Schenkein DS, Miller KB. Vancomycin-resistant enterococcal infections in bone marrow transplant recipients. Bone Marrow Transplant 1998; 22: 207-209.
22. DesJardin JA, Falagas ME, Ruthazer R, Griffith J, Wawrose D, Schenkein D et al. Clinical utility of blood cultures drawn from indwelling central venous catheters in hospitalized patients with cancer. Ann Intern Med 1999; 131: 641-647.
23. Miller KB, Roberts TF, Chan G, Schenkein DP, Lawrence D, Sprague K et al. A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease. Bone Marrow Transplant 2004; 33: 881-889.
24. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
25. Shoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 1982; 69: 239-241.
26. Harrell Jr FE. %daspline.sas. Mayo Foundations for Medical Education and Research, Copyright 2006, 1991.
27. Bergstralh E, Therneau T. %Schoen.sas. Mayo Foundations for Medical Education and Research, Copyright 2006 2002.
28. Allison PD. Survival Analysis Using SAS(TM): A Practical Guide Estimating Cox Regression Models with PROC PHREG. SAS Institute Inc.: Cary, NC, 1995.
29. Gordis L. More on risk: Estimating the potential for prevention. In: Epidemiology. Elsevier Saunders: Philadelphia, 2004, pp 191-198.
30. Cometta A, Zinner S, deBock R, Calandra T, Gaya H, Klastersky J et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1995; 39: 445-452.
31. De Pauw B, Donnelly J. Infections in the immunocompromised host: General principles. In: Mandell J, Bennett J, Dolin R(eds). Principles and Practice of Infectious Diseases, 5th edn. Churchill Livingstone: Philadelphia, 2000, pp 3079-3090.
32. Kulkarni S, Powles R, Treleaven J, Riley U, Singhal S, Horton C et al. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood 2000; 95: 3683-3686.
33. Ip MS, Yuen KY, Woo PC, Luk WK, Tsang KW, Lam WK et al. Risk factors for pulmonary tuberculosis in bone marrow transplant recipients. Am J Respir Crit Care Med 1998; 158: 1173-1177.
34. Ochs L, Shu X, Miller J, Enright H, Wagner J, Filipovich A et al. Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients. Blood 1995; 86: 3979-3986.
35. Vergis EN, Hayden MK, Chow JW, Snydman DR, Zervos MJ, Linden PK et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. A prospective multicenter study. Ann Intern Med 2001; 135: 484-492.
36. DiazGranados CA, Jernigan JA. Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. J Infect Dis 2005; 191: 588-595.
37. Papanicolaou GA, Meyers BR, Meyers J, Mendelson MH, Lou W, Emre S et al. Nosocomial infections with vancomycinresistant Enterococcus faecium in liver transplant recipients: Risk factors for acquisition and mortality. Clin Infect Dis 1996; 23: 760-766.
38. Pizzo P, Hathorn J, Hiemenz J, Browne M, Commers J, Cotton D et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. New Engl J Med 1986; 315: 552-558.
39. De Pauw B, Deresinski S, Feld R, Lane-Allman E, Donnelly J. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. Ann Intern Med 1994; 120: 834-844.
40. Cordonnier C, Herbrecht R, Luis Pico J, Gardembas M, Delmer A, Delain M et al. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: A comparative study. Clin Infect Dis 1997; 24: 41-51.
41. Anonymous. From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. J Infect Dis 1990; 161: 397-401.
42. Hughes WT, Pizzo PA, Wade JC, Armstrong D, Webb CD, Young LS. Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Infectious Diseases Society of America and the Food and Drug Administration [comment]. Clin Infect Dis 1992; 15(Suppl 1): S206-S215.
43. Schots R, Trullemans F, Van Riet I, Kaufman L, Hafsia A, Meddeb B et al. The clinical impact of early gram-positive bacteremia and the use of vancomycin after allogeneic bone marrow transplantation. Transplantation 2000; 69: 1511-1514.
44. Nucci M, Andrade F, Vigorito A, Trabasso P, Aranha JF, Maiolino A et al. Infectious complications in patients randomized to receive allogeneic bone marrow or peripheral blood transplantation. Transpl Infect Dis 2003; 5: 167-173.
45. Daly A, McAfee S, Dey B, Colby C, Schulte L, Yeap B et al. Nonmyeloablative bone marrow transplantation: Infectious complications in 65 recipients of HLA-identical and mismatched transplants. Biol Blood Marrow Transplant 2003; 9: 373-382.